{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:06:11Z","timestamp":1776150371838,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128357","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:25:58Z","timestamp":1771604758000},"page":"128357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study"],"prefix":"10.1016","volume":"77","author":[{"given":"Khursheed","family":"Anwer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Musso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninaad","family":"Lasrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ai-Ris-Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subeena","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Blume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean D.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas V.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy R.","family":"Lindborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2026.128357_bb0005","article-title":"A comparison of plasmid DNA and mRNA as vaccine technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128357_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.633776","article-title":"A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications","volume":"9","author":"Qin","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.vaccine.2026.128357_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115340","article-title":"A comprehensive comparison of DNA and RNA vaccines","volume":"210","author":"Wang","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"issue":"23","key":"10.1016\/j.vaccine.2026.128357_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168297","article-title":"DNA vaccines: history, molecular mechanisms and future perspectives","volume":"435","author":"Pagliari","year":"2023","journal-title":"J Mol Biol"},{"issue":"6505","key":"10.1016\/j.vaccine.2026.128357_bb0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128357_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118919","article-title":"DNA vaccines against COVID-19: perspectives and challenges","volume":"267","author":"Silveira","year":"2021","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128357_bb0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.1874","article-title":"Rational design of gene-based vaccines","volume":"208","author":"Barouch","year":"2006","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128357_bb0040","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.vaccine.2024.01.065","article-title":"Strong immunogenicity & protection in mice with PlaCCine: a COVID-19 DNA vaccine formulated with a functional polymer","volume":"42","author":"Sood","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128357_bb0045","doi-asserted-by":"crossref","unstructured":"Sood, S., et al., Intramuscular DNA vaccine provides protection in non-human primate and mouse models of SARS-CoV-2. Front Immunol, 2025. 16: p. 1589584.","DOI":"10.3389\/fimmu.2025.1589584"},{"key":"10.1016\/j.vaccine.2026.128357_bb0050","doi-asserted-by":"crossref","unstructured":"Lasrado, N., et al., SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity. Sci Transl Med, 2024. 16(770): p. eadp8920.","DOI":"10.1126\/scitranslmed.adp8920"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128357_bb0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis with COVID-19 mRNA vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2026.128357_bb0060","doi-asserted-by":"crossref","unstructured":"Fairweather, D., et al., COVID-19, myocarditis and pericarditis. Circ Res, 2023. 132(10): p. 1302\u20131319.","DOI":"10.1161\/CIRCRESAHA.123.321878"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128357_bb0065","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S1473-3099(24)00603-0","article-title":"Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination","volume":"24","author":"Happle","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"10.1016\/j.vaccine.2026.128357_bb0070","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128357_bb0075","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.vaccine.2026.128357_bb0080","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128357_bb0085","article-title":"Immunogenicity of the monovalent omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine against XBB.1.5, BA.2.86, and JN.1 sublineages: a phase 2\/3 trial","volume":"12","author":"Gayed","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128357_bb0090","doi-asserted-by":"crossref","unstructured":"Pradenas, E., et al., Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters. J Transl Med, 2025. 23(1): p. 783.","DOI":"10.1186\/s12967-025-06837-0"},{"key":"10.1016\/j.vaccine.2026.128357_bb0095","doi-asserted-by":"crossref","unstructured":"Jacobsen, H., et al., Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2. NPJ Vaccines, 2023. 8(1): p. 159.","DOI":"10.1038\/s41541-023-00756-1"},{"key":"10.1016\/j.vaccine.2026.128357_bb0100","doi-asserted-by":"crossref","unstructured":"Chen, Z., et al., Waning neutralizing antibodies through 180\u00a0days after homologous and heterologous boosters of inactivated COVID-19 vaccine. Front Public Health, 2025. 13: p. 1478627.","DOI":"10.3389\/fpubh.2025.1478627"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128357_bb0105","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra2206573","article-title":"Covid-19 vaccines - immunity, variants, boosters","volume":"387","author":"Barouch","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128357_bb0110","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014035","article-title":"Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine","volume":"5","author":"Chien","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128357_bb0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/hmg\/1.6.363","article-title":"Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle","volume":"1","author":"Wolff","year":"1992","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128357_bb0120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1056\/NEJMc2213948","article-title":"Immunogenicity of BA.5 bivalent mRNA vaccine boosters","volume":"388","author":"Collier","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128357_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/CCID.S162724","article-title":"Current trends in needle-free jet injection: an update","volume":"11","author":"Barolet","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.vaccine.2026.128357_bb0130","series-title":"Application of nanotechnology in drug delivery","first-page":"369","article-title":"Electroporation \u2013 Advantages and drawbacks for delivery of drug, gene and Vaccine","author":"Bolhassani","year":"2014"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128357_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47020091","article-title":"Electroporation induces unexpected alterations in gene expression: a tip for selection of optimal transfection method","volume":"47","author":"Hamada","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128357_bb0140","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1006\/mthe.2001.0483","article-title":"Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188","volume":"4","author":"Hartikka","year":"2001","journal-title":"Mol Ther"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128357_bb0145","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T06:26:40Z","timestamp":1776148000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26001659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":29,"alternative-id":["S0264410X26001659"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128357","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128357"}}